Sort by: after hours percent change | delayed percent change | gain open | gain high | gain close | publishing date
tags : Disease save search
Valued to be $12.9 Billion by 2026, Crohn`s Disease (CD) Therapy Slated for Robust Growth Worldwide
Published: 2022-06-27 (Crawled : 12:20) - prnewswire.com
NVO | News | $112.89 0.69% 0.0% |
|
Health Technology
|
| O: 0.78%
H: 0.97%
C: 0.19%
CCXI | News | $26.01 -0.53% -4.4% |
|
Health Technology
|
| O: -4.88%
H: 1.04%
C: -1.25%
AZN | News | $66.465 -0.65% -0.42% |
|
Health Technology
|
| O: -0.36%
H: 1.22%
C: 0.38%
AZNCF | News | $129.21 |
|
Health Technology
|
| O: -1.55%
H: 4.43%
C: 0.03%
NVS | News | $85.28 0.53% 0.02% |
|
Health Technology
|
| O: 1.86%
H: 1.05%
C: 0.24%
PFE | News | $51.88 0.56% 0.04% |
|
Health Technology
|
| O: 1.46%
H: 1.45%
C: 0.78%
JNJ | News | $182.12 -0.09% 0.1% |
|
Health Technology
|
| O: 0.78%
H: 0.94%
C: 0.26%
disease for therapy growth
Beam Therapeutics to Present First Research Highlighting Approach to Develop Non-Genotoxic Conditioning Regimens for Patients with Sickle Cell Disease Ahead of Autologous Transplant
Published: 2022-06-27 (Crawled : 11:00) - globenewswire.com
BEAM | News | $43.19 1.6% 1.15% |
|
Health Technology
|
| O: 0.21%
H: 2.94%
C: 0.65%
research disease for therapeutics
Astellas Announces FDA Update on the FORTIS Clinical Trial of AT845 in Adults with Late-Onset Pompe Disease
Published: 2022-06-27 (Crawled : 08:00) - biospace.com/
ALPMY | News | $16.205 |
|
Manufacturing
|
| O: -1.2%
H: 0.0%
C: -0.37%
at845 fda disease trial update
Astellas Announces FDA Update on the FORTIS Clinical Trial of AT845 in Adults with Late-Onset Pompe Disease
Published: 2022-06-26 (Crawled : 00:00) - prnewswire.com
ALPMY | News | $16.205 |
|
Manufacturing
|
| O: -1.2%
H: 0.0%
C: -0.37%
at845 fda disease trial update
ProKidney Corroborates the Mechanism of Action of REACT™ with Cell Marker Analysis in Patients with Diabetic Chronic Kidney Disease
Published: 2022-06-23 (Crawled : 17:00) - biospace.com/
DNAC | $9.975 0.05% 0.05% |
|
|
| O: 0.16%
H: 0.05%
C: -0.11%
disease kidney diabetic
uniQure Announces Update on Low-Dose Cohort in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
Published: 2022-06-23 (Crawled : 12:00) - biospace.com/
QURE S | $18.69 -2.2% -2.67% |
|
Health Technology
|
| O: 11.64%
H: 14.76%
C: 14.47%
amt-130 treatment disease for trial therapy update
Novartis renews commitment to neglected tropical disease and malaria elimination, investing USD 250 million over five years to research and develop new treatments
Published: 2022-06-23 (Crawled : 01:00) - globenewswire.com
NVS | News | $85.28 0.53% 0.02% |
|
Health Technology
|
| O: 0.3%
H: 0.0%
C: 0.0%
research disease novartis
U.S. FDA Approves Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Infants and Children
Published: 2022-06-22 (Crawled : 17:00) - biospace.com/
MRK | News | $94.41 1.37% 0.27% |
|
Health Technology
|
| O: 3.24%
H: 2.61%
C: 1.27%
fda disease for children
Cyclerion Therapeutics to Discuss CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation
Published: 2022-06-22 (Crawled : 13:00) - ir.cyclerion.com
CYCN | $0.6046 14.05% 13.19% |
|
Health Technology
|
| O: -0.5%
H: 9.6%
C: 1.4%
cy6463 disease therapeutics
BioRestorative Therapies Announces Clinical Trial Contract with Second Site for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)
Published: 2022-06-22 (Crawled : 12:20) - biospace.com/
BRTXQ P | $ 0% |
|
Health Services
| Email alert
Add to watchlist
BRTXD | $ 0% |
|
Professional, Scientific, and T...
| Email alert
Add to watchlist
BRTX | $3.43 -0.29% -1.16% |
|
Professional, Scientific, and T...
| Email alert
Add to watchlist
disease for contract trial
BridgeBio Pharma Announces Early Positive Data for BBP-812, its Investigational AAV9 Gene Therapy for Canavan Disease
Published: 2022-06-22 (Crawled : 12:00) - biospace.com/
BBIO | News A | $9.34 1.08% -0.43% |
|
Health Technology
|
| O: -1.02%
H: 12.96%
C: 8.61%
bbp-812 pharma disease for aav9 positive therapy
Athira Pharma Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
Published: 2022-06-22 (Crawled : 12:00) - biospace.com/
ATHA S | $2.85 4.02% -0.37% |
|
Health Technology
|
| O: -69.76%
H: 17.42%
C: 7.95%
pharma disease topline alzheimer’s results act-ad phase 2 ath-1017
Regulus Therapeutics Announces Receipt of FDA Orphan Drug Designation for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Published: 2022-06-21 (Crawled : 16:00) - biospace.com/
RGLS | $0.225 -6.48% 5.99% |
|
Health Technology
|
| O: 3.45%
H: 0.0%
C: 0.0%
rgls8429 treatment fda designation drug disease for kidney therapeutics
Gilead to Present Latest Data From Across Liver Disease Development Programs at the International Liver Congress™ 2022
Published: 2022-06-21 (Crawled : 14:00) - biospace.com/
GILD | $62.84 -0.38% -0.13% |
|
Health Technology
|
| O: 1.34%
H: 0.0%
C: 0.0%
liver disease international
Cyclo Therapeutics to Present at the 2022 NPC Patient and Family Conference Hosted by the Australian NPC Disease Foundation
Published: 2022-06-21 (Crawled : 13:20) - biospace.com/
CYTH | $2.1 4.76% |
|
Professional, Scientific, and T...
|
| O: -2.68%
H: 0.0%
C: 0.0%
conference disease therapeutics
9 Meters Biopharma Announces Interim Analysis of Phase 3 Study of Larazotide for Celiac Disease Does Not Support Trial Continuation
Published: 2022-06-21 (Crawled : 13:00) - biospace.com/
NMTR A | $0.4011 5.55% -7.9% |
|
Health Technology
|
| O: -53.55%
H: 0.0%
C: 0.0%
biopharma disease for trial
ANI Pharmaceuticals Adopts Veeva Commercial Cloud to Better Support Rare Disease Patients
Published: 2022-06-21 (Crawled : 12:00) - biospace.com/
VEEV S | $208.07 0.5% 0.0% |
|
Technology Services
|
| O: 4.75%
H: 0.0%
C: 0.0%
ANIP | $30.095 4.1% 0.0% |
|
Health Technology
|
| O: 2.34%
H: 0.0%
C: 0.0%
rare disease commercial cloud
Ocugen Announces Publication of Positive Results of COVID-19 Vaccine Trial for Children 2-18 in The Lancet Infectious Diseases
Published: 2022-06-21 (Crawled : 12:00) - biospace.com/
OCGN | $2.435 -2.99% -0.8% |
|
Health Technology
|
| O: 10.89%
H: 0.0%
C: 0.0%
covid-19 for children vaccine lancet trial positive results publication disease
SQZ Biotechnologies Presents Celiac Disease Tolerizing Antigen Carrier Preclinical Data at 2022 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting
Published: 2022-06-21 (Crawled : 11:00) - biospace.com/
SQZ | $3.37 -4.53% 2.97% |
|
Health Technology
|
| O: 2.92%
H: 0.0%
C: 0.0%
disease preclinical sqz immunology meeting
Emergent BioSolutions Announces Publication of CHIKV VLP Phase 2 Safety and Immunogenicity Data in The Lancet Infectious Diseases
Published: 2022-06-21 (Crawled : 11:00) - globenewswire.com
EBS | $32.65 -0.34% 0.0% |
|
Health Technology
|
| O: 5.29%
H: 0.0%
C: 0.0%
lancet publication chikungunya disease
Your saved searches
Save your searches and get alerts when important news are released.
Mentioned Today
ABBV | News | $153.14 0.53% 0.04% |
|
Health Technology
APPN | News 4 | $54.46 -1.05% 0.38% |
|
Technology Services
APPS | News | $17.62 1.62% 5.48% |
|
Technology Services
APYX | News | $6.04 1.51% 0.0% |
|
Health Technology
BNPQF | News | $50.78 |
|
Finance
BNPQY | News | $25.46 |
|
Finance and Insurance
BNPZY | News | $ 0% |
|
Finance and Insurance
CNXC | News | $147.67 1.63% -0.04% |
|
Information
CNXCV | News | $2.27 0% |
|
Commercial Services
DMYD | News | $16.21 0% |
|
Finance
DMYT | News | $22.76 0% |
|
Finance
DRE | News | $56.17 -2.23% 0.0% |
|
Finance
EPZM | News | $1.47 54.09% 7.97% |
|
Health Technology
ET | News | $10.14 0.4% 0.59% |
|
Industrial Services
FBNC | News | $35.7 2.32% 0.0% |
|
Finance
FBP | News | $13.52 0.67% 0.0% |
|
Finance
FTRP | News | $0.81 1.25% 0.0% |
|
Health Care and Social Assistan...
GRRB | News | $30.6 |
|
Finance and Insurance
HR | News | $27.23 1.38% 0.0% |
|
Finance
HTA | News | $27.7 -0.22% 0.0% |
|
Finance
IE | News 0 d new | $ 0% |
|
n/a
IONQ | News | $4.83 -5.48% 2.07% |
|
Professional, Scientific, and T...
LLY | News 4 | $327.27 0.51% 0.04% |
|
Health Technology
LMPX | News | $4.62 0.43% 0.0% |
|
Technology Services
NFLX | News | $189.14 -0.9% 0.52% |
|
Consumer Services
OBCI | News | $12.86 0.0% |
|
Consumer Non-Durables
OMC | News | $64.75 0.23% 0.0% |
|
Commercial Services
ONEW | News | $35.25 3.68% 0.0% |
|
Retail Trade
OSCR | News | $4.55 2.94% 0.0% |
|
PACB | News | $5.3 -5.53% -1.78% |
|
Health Technology
PEGA | News | $51.68 -1.97% 0.0% |
|
Technology Services
PFHC | News | $19.75 6.35% -4.95% |
|
PLD | News | $120.21 -1.94% 0.54% |
|
Finance
PSORF | News | $9.55 0% |
|
Consumer Services
RDUS | News | $10.205 0.94% -0.4% |
|
Health Technology
SNY | News | $52.62 -1.5% -0.41% |
|
Health Technology
SNYNF | News | $104.5 |
|
Health Technology
SPRO | News | $0.931 -0.96% 3.19% |
|
Health Technology
SREV | News | $1.45 -2.76% |
|
Technology Services
TGTX | News | $4.34 -1.36% -2.05% |
|
Health Technology
TUP | News 4 | $7.16 1.42% 0.0% |
|
Producer Manufacturing
USAK | News | $30.85 -0.48% -0.39% |
|
Transportation
USWS | News | $0.995 4.08% -0.63% |
|
Finance
VRCA | News | $2.195 4.03% 10.43% |
|
Health Technology
WWE | News | $61.0 0.63% 0.0% |
|
Consumer Services
XRAY | News | $36.74 -0.05% 0.0% |
|
Health Technology
ZEN | News | $74.65 0.65% -0.07% |
|
Technology Services